Vericel Corporation
VCEL
Positions held
Your positionsVCEL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Vericel Corporation operates in the biotechnology sector, which is characterized by rapid innovation and strong demand for advanced therapies, positioning it well for future growth.
- In Q2 2026, Vericel reported a revenue increase of 13% compared to the previous quarter, reaching $77 million.
- The gross margin improved to 72.8% in Q2 2026, up from 72% in Q1 2026.
- The biotechnology industry faces intense competition and regulatory scrutiny, which can impact product development timelines and market entry.
- Vericel's operating margin was only 0.6% in Q2 2026, indicating challenges in profitability despite revenue growth.
- The company's overall score is a 'Sell' with a score of -5.00, reflecting negative trends in key performance indicators.
Fundamentals
| Market cap | $2.05B | Enterprise value | $1.98B | Trailing P/E | 85.21 | Forward P/E | 47.34 |
| PEG | — | Price / book | 5.54 | Beta | 1.03 | Dividend yield | 0.00% |
| Revenue growth | 22.5% | Earnings growth | — | Gross margin | 74.6% | Operating margin | 0.6% |
| Profit margin | 7.9% | ROE | 7.2% | ROA | 2.4% | Debt / equity | 0.25 |
| Current ratio | 5.04 | Free cash flow | $55.54M | Analyst recommendation | none | Mean target | $60.57 |
| 52w high | $49.32 | 52w low | $28.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $77.5M | $68.4M | $92.9M | $67.5M | $63.2M |
| Op margin | 0.6% | -11.8% | 24.1% | 5.1% | -3.2% |
| Net income | $2.2M | -$6.3M | $23.2M | $5.1M | -$0.6M |
| Gross margin | 72.8% | 72.0% | 78.7% | 73.5% | 73.7% |
| Gross profit | $56.4M | $49.3M | $73.1M | $49.6M | $46.6M |
| Operating income | $0.4M | -$8.1M | $22.4M | $3.5M | -$2.0M |
- Revenue +13% vs prior quarter ($77M vs $68M).
- Gross margin 72.8% (was 72% prior quarter).
- Operating margin expanded to 0.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $276M | $237M | $198M | $164M |
| Op margin | 4.0% | 1.9% | -3.3% | -10.4% |
| Net income | $16.5M | $10.4M | -$3.2M | -$16.7M |
| Gross margin | 74.4% | 72.6% | 68.6% | 66.8% |
| Gross profit | $206M | $172M | $136M | $110M |
| Operating income | $11.0M | $4.5M | -$6.5M | -$17.1M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-26 · Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain
2026-09-08 · Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
2026-08-13 · MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-03 · Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison
2026-07-31 · Truist Raises Price Target on Vericel to $58 From $54, Keeps Buy Rating
2026-07-30 · Vericel Q2 Earnings Call Highlights
2026-07-30 · Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
2026-07-30 · Vericel Swings to Q2 Net Income, Revenue Rises; Full-Year 2026 Revenue Guidance Raised
2026-07-16 · Truist Securities Adjusts Price Target on Vericel to $54 From $42, Maintains Buy Rating
2026-07-16 · Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
Price (daily)
Full chart · RSI · MACD · patterns